Spatiotemporal quantification of HER2-targeting antibody-drug conjugate bystander activity and enhancement of solid tumor penetration.
Qing WeiTeng YangJiayu ZhuZiwen ZhangLe YangYuchao ZhangXiang-Dong ChengJiahui ChenJinchao WangXuefei TianTakaya ShimuraJianmin FangJie-Er YingMengyang FanPeng GuoXiangdong ChengPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
These promising preclinical data allowed us to initiate a phase I/II clinical study of co-administration of RC48 and trastuzumab in patients with malignant stomach cancer to further evaluate this treatment strategy in humans.